# OnCo record paper-dellphi-301-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-dellphi-301-nejm-2023" ;
  schema:name "DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer"@en ;
  schema:description "A bispecific antibody that pulls T cells onto small-cell lung cancer cells produced responses in 40% of patients whose cancer had come back after chemotherapy, lasting far longer than any previous drug in this setting."@en ;
  schema:url <https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2307980>, <https://clinicaltrials.gov/study/NCT05060016>, <https://pubmed.ncbi.nlm.nih.gov/37861218/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2307980> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Ahn MJ, Cho BC, Felip E, et al." ;
  onco:related <https://onco.cc/key-papers/paper-tarlatamab-sclc-n-engl-j-med-2025/>, <https://onco.cc/key-papers/paper-dll3-sclc-clin-cancer-res-2019/>, <https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/> ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/cd3/> ;
  onco:drugs <https://onco.cc/drugs/tarlatamab/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:institutions <https://onco.cc/institutions/samsung-medical-center/> ;
  onco:terms <https://onco.cc/terms/orr/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/accelerated-approval/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/dellphi-304/> ;
  onco:people <https://onco.cc/people/ahn-myung-ju/>, <https://onco.cc/people/cho-byoung-chul/>, <https://onco.cc/people/enriqueta-felip/>, <https://onco.cc/people/juergen-wolf/>, <https://onco.cc/people/fiona-blackhall/>, <https://onco.cc/people/luis-paz-ares/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-care-fragmentation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .